1887

Abstract

The immunomodulating and murine cytomegalovirus (MCMV)-inhibiting effects of the synthetic lipid A subunit analogue GLA-60 were investigated in different strains of immunodeficient mice. Peritoneal natural killer (NK) cells obtained from nude (nu/nu) C57BL/6 mice or normal NMRI mice, which had been treated intraperitoneally with 10 µg of GLA-60 1 day earlier, exhibited a greater cytolytic activity than those from untreated mice. GLA-60 also stimulated NK cell activity in SCID (severe combined immune deficiency) mice (which are T and B cell-defective), but not in NK cell-defective beige (C57BL/6 bg/bg) mice. GLA-60 also enhanced the phagocytic activity of peritoneal macrophages in beige, nude and NMRI mice, but not in SCID mice. GLA-60, when administered as a single 150 µg dose 1 day before infection, completely protected beige mice against MCMV-associated mortality. It also caused a significant increase in the life-span of MCMV-infected nude and SCID mice.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-74-7-1399
1993-07-01
2021-10-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/74/7/JV0740071399.html?itemId=/content/journal/jgv/10.1099/0022-1317-74-7-1399&mimeType=html&fmt=ahah

References

  1. Araullo-Cruz T, Ho , Armstrong J. 1978; Protective effect of early serum from mice after cytomegalovirus infection. Infection and Immunity 21:3840–842
    [Google Scholar]
  2. Bosma G, Custer R, Bosma MJ. 1983; A severe combined immunodeficiency mutation in the mouse. Nature 301:527–530
    [Google Scholar]
  3. Britt WJ, Pass RF, Stagno S, Alford CA. 1991; Pediatric cytomegalovirus infection. Transplantation Proceedings 23:115–117
    [Google Scholar]
  4. Emanuel D. 1990; Treatment of cytomegalovirus disease. Seminars in Hematology 1:22–27
    [Google Scholar]
  5. Erice A, Sunwe C, Biron KK, Stanat SC, Balfour HH, Jordan MC. 1989; Progressive Disease Due to Ganciclovir-Resistant Cytomegalovirus in Immunocompromised Patients.. New England Journal of Medicine 320:289–293
    [Google Scholar]
  6. Ikeda S, Kumazawa Y, Nishimura C, Nakatsuka M, Homma JY, Kiso M, Hasegawa A. 1988a; Enhancement of nonspecific resistance to viral infection by chemically synthesized lipid A-subunit analogs with different backbone structures and acyl groups. Antiviral Research 10:167–178
    [Google Scholar]
  7. Ikeda S, Nishimura C, Nakatsuka M, Yuzuru Homma J, Kiso M, Hasegawa A. 1988b; Antiviral and immunomodulating activities of chemically synthesized lipid A-subunit analogues GLA-27 and GLA-60. Antiviral Research 9:37–46
    [Google Scholar]
  8. Ikeda S, Tominaga T, Nishimura C, Homma JY, Kiso M, Hasegawa A. 1989; Antiherpes activity of chemically synthesized lipid A-subunit analogue GLA-60 in immunosuppressed mice. Antiviral Research 11:173–180
    [Google Scholar]
  9. Ikeda S, Kaneko M, Nishiya S, Nishimura C. 1990; Restoration of hematopoietic activity by lipid A analogue GLA-60 in cyclophosphamide-treated immunosuppressed mice. Journal of Clinical Laboratory Immunology 32:93–93
    [Google Scholar]
  10. Ikeda S, Neyts J, Matsuura M, Kiso M, Hasegawa A, Nishimura C, De Clercq E. 1993; Protective activity of lipid A analogue GLA-60 against murine cytomegalovirus infection in mice.. Journal of Medical Virology 40:222–227
    [Google Scholar]
  11. Janeway CA. 1989; A primitive immune system. Nature 341:108–108
    [Google Scholar]
  12. Kiso M, Tanaka S, Fujita M, Fujishima Y, Ogawa Y, Ishida H, Hasegawa A. 1987; Synthesis of the optically active 4-O-phosphono-d-glucosamine derivatives related to the nonreducing-sugar subunit of bacterial lipid A.. Carbohydrate Research 162:127–140
    [Google Scholar]
  13. Kumazawa Y, Nakatsuka M, Takimoto H, Furuya T, Nagumo T, Yamamoto A, Homma Y, Inada K, Yoshida M, Kiso M. 1988; Importance of fatty acid substituents of chemically synthesized lipid A-subunit analogs in the expression of immunopharmacological activity.. Infection and Immunity 56:149–155
    [Google Scholar]
  14. Manischewitz JE, Quinnan GV. 1980; Antivirus antibody-dependent cell-mediated cytotoxicity during murine cytomegalovirus infection.. Infection and Immunity 29:1050–1054
    [Google Scholar]
  15. Matsuura M, Kojima Y, Homma JY, Kubota Y, Shibukawa N, Shibata M, Inage M, Kusumoto S, Shiba T. 1983; Interferon-inducing, pyrogenic and proclotting enzyme of horseshoe crab activation activities of chemically synthesized lipid A analogues.. European Journal of Biochemistry 137:639–642
    [Google Scholar]
  16. Morahan PS. 1984; Interactions of herpesviruses with mononuclear phagocytes.. In Immunology of Herpes Simplex Virus InfectionEdited by Rouse BT, Lopez C. Boca Raton: CRC Press.; pp 71–89
    [Google Scholar]
  17. Nakatsuka M, Kumazawa Y, Matsuura M, Homma JY, Kiso M, Hasegawa A. 1989; Enhancement of nonspecific resistance to bacterial infections and tumor regressions by treatment with synthetic lipid A-subunit analogs. Critical role of N- and 3-O-linked acyl groups in derivatives.. International Journal of Immunopharmacology 11:349–358
    [Google Scholar]
  18. Nakatsuka M, Kumazawa Y, Homma JY, Kiso M, Hasegawa A. 1991; Inhibition in mice of experimental metastasis of B 16 melanoma by the synthetic lipid A-subunit analogue GLA-60.. International Journal of Immunopharmacology 13:11–19
    [Google Scholar]
  19. Neyts J, Balzarini J, Naesens L, de Clercq E. 1992; Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice.. Journal of Medical Virology 37:67–71
    [Google Scholar]
  20. Quinnan GV, Manischewitz JE. 1979; The role of natural killer cells and antibody-dependent cell-mediated cytotoxicity during murine cytomegalovirus infection.. Journal of Experimental Medicine 150:1549–1554
    [Google Scholar]
  21. Rubin RH. 1990; Impact of Cytomegalovirus Infection on Organ Transplant Recipients.. Reviews of Infectious Diseases 12, Supplement 7:754–766
    [Google Scholar]
  22. Saiki I, Maeda H, Murata J, Yamamoto N, Kiso M, Hasegawa A, Azuma I. 1989; Antimetastatic effect of endogenous tumor necrosis factor induced by the treatment of recombinant interferon γ followed by an analogue (GLA-60) to synthetic lipid A subunit. Cancer Immunology Immunotherapy 30:151–157
    [Google Scholar]
  23. Saiki I, Maeda M, Murata J, Takahashi T, Sekiguchi S, Kiso M, Hasegawa A, Azuma I. 1990; Production of interleukin 1 from human monocytes stimulated by synthetic lipid A subunit analogues.. International Journal of Immunopharmacology 12:297–305
    [Google Scholar]
  24. Selgrade MK, Huang YS, Graham JA, Huang CH, Hu PC. 1983; Humoral antibody response to individual viral proteins after murine cytomegalovirus infection. Journal of Immunology 131:3032–3035
    [Google Scholar]
  25. Shanley JD, Jordan MC, Stevens JG. 1981; Modification by Adoptive Humoral Immunity of Murine Cytomegalovirus Infection. Journal of Infectious Diseases 143:231–237
    [Google Scholar]
  26. Shellam GR, Allan JE, Papadimitriou JM, Bancroft GJ. 1981; Increased susceptibility to cytomegalovirus infection in beige mutant mice.. Proceedings of the National Academy of Sciences 78:5104–5108
    [Google Scholar]
  27. Shellam GR, Flexman JP, Farrell HE, Papadimitriou JM. 1985; The Genetic Background Modulates the Effect of the Beige Gene on Susceptibility to Cytomegalovirus Infection in Mice. Scandinavian Journal of Immunology 22:147–155
    [Google Scholar]
  28. Staczeik J. 1990; Animal cytomegaloviruses.. Microbiological Reviews 54:247–265
    [Google Scholar]
  29. Stagno S, Pass RF, Dworsky ME, Henderson RE, Moore EG, Walton PD, Alford CD. 1982 New England Journal of Medicine Congenital cytomegalovirus infections: the relative importance of primary and recurrent maternal infections.. 306:945–949
    [Google Scholar]
  30. Starr SE, Allison AC. 1977; Role of T lymphocytes in recovery from murine cytomegalovirus infection.. Infection and Immunity 17:458–462
    [Google Scholar]
  31. Tyms AS, Taylor DL, Parkin JM. 1989; Cytomegalovirus and the acquired immunodeficiency syndrome. Journal of Antimicrobial Chemotherapy 23:89–105
    [Google Scholar]
  32. Verheyden JPH. 1988; Evolution of Therapy for Cytomegalovirus Infection.. Reviews of Infectious Diseases 10, Supplement 3:5477–5489
    [Google Scholar]
  33. Welsh RM, Brubaker JO, Vargas-Cortes M, O'Donnell CL. 1991; Natural killer (NK) cell response to virus infections in mice with severe combined immunodeficiency. The stimulation of NK cells and the NK cell-dependent control of virus infections occur independently of T and B cell function.. Journal of Experimental Medicine 173:1053–1063
    [Google Scholar]
  34. Winston DJ, Ho WG, Champlin RE. 1990; Cytomegalovirus Infections After Allogeneic Bone Marrow Transplantation. Reviews of Infectious Diseases 12, Supplement 7:776–791
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-74-7-1399
Loading
/content/journal/jgv/10.1099/0022-1317-74-7-1399
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error